Novartis AG Company Profile (NYSE:NVS)

About Novartis AG (NYSE:NVS)

Novartis AG logoNovartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $200.88 billion
  • Outstanding Shares: 2,342,890,000
Average Prices:
  • 50 Day Moving Avg: $85.60
  • 200 Day Moving Avg: $82.21
  • 52 Week Range: $66.93 - $86.90
P/E:
  • Trailing P/E Ratio: 31.30
  • Foreward P/E Ratio: 16.43
  • P/E Growth: 2.94
Sales & Book Value:
  • Annual Revenue: $49.18 billion
  • Price / Sales: 4.08
  • Book Value: $29.84 per share
  • Price / Book: 2.87
Dividend:
  • Annual Dividend: $2.30
  • Dividend Yield: 3.2%
Profitability:
  • EBITDA: $14.46 billion
  • Net Margins: 15.84%
  • Return on Equity: 11.55%
  • Return on Assets: 5.97%
Debt:
  • Debt-to-Equity Ratio: 0.33%
  • Current Ratio: 1.01%
  • Quick Ratio: 0.75%
Misc:
  • Average Volume: 1.55 million shs.
  • Beta: 0.73
  • Short Ratio: 1.69
 

Frequently Asked Questions for Novartis AG (NYSE:NVS)

What is Novartis AG's stock symbol?

Novartis AG trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

How often does Novartis AG pay dividends? What is the dividend yield for Novartis AG?

Novartis AG announced an annual dividend on Friday, January 27th. Investors of record on Friday, March 3rd will be paid a dividend of $2.327 per share on Friday, March 3rd. The ex-dividend date is Wednesday, March 1st. View Novartis AG's Dividend History.

How will Novartis AG's stock buyback program work?

Novartis AG declared that its board has authorized a stock buyback plan on Saturday, April 8th 2017, which permits the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to purchase up to 2.9% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's board of directors believes its shares are undervalued.

How were Novartis AG's earnings last quarter?

Novartis AG (NYSE:NVS) posted its quarterly earnings data on Tuesday, July, 19th. The company reported $1.23 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.18 by $0.05. The business had revenue of $12.47 billion for the quarter, compared to the consensus estimate of $12.33 billion. Novartis AG had a return on equity of 11.55% and a net margin of 15.84%. During the same period in the previous year, the business posted $1.25 earnings per share. View Novartis AG's Earnings History.

When will Novartis AG make its next earnings announcement?

Novartis AG is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Novartis AG.

Where is Novartis AG's stock going? Where will Novartis AG's stock price be in 2017?

13 brokerages have issued 12-month price targets for Novartis AG's stock. Their forecasts range from $74.37 to $90.00. On average, they expect Novartis AG's share price to reach $82.92 in the next twelve months. View Analyst Ratings for Novartis AG.

Are investors shorting Novartis AG?

Novartis AG saw a decline in short interest in September. As of September 15th, there was short interest totalling 1,327,917 shares, a decline of 33.5% from the August 31st total of 1,996,918 shares. Based on an average daily volume of 1,788,278 shares, the days-to-cover ratio is currently 0.7 days.

Who are some of Novartis AG's key competitors?

Who are Novartis AG's key executives?

Novartis AG's management team includes the folowing people:

  • Joseph S. Jimenez, Chief Executive Officer, Member of the Executive Committee
  • Harry Kirsch, Chief Financial Officer, Member of the Executive Committee
  • Michael Ball, Chief Executive Officer of Alcon, Member of the Executive Committee
  • James Bradner M.D., President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee
  • Richard D. Francis, Chief Executive Officer of Sandoz Division, Member of the Executive Committee
  • Paul Hudson, Chief Executive Officer of Novartis Pharmaceuticals, Member of the Executive Committee
  • Bruno Strigini, Chief Executive Officer of Novartis Oncology, Member of the Executive Committee
  • Felix R. Ehrat Ph.D., Group General Counsel, Member of the Executive Committee
  • Steven Baert, Head of Human Resources, Member of the Executive Committee
  • Vasant Narasimhan M.D., Chief Executive Officer, Member of the Executive Committee

Who owns Novartis AG stock?

Novartis AG's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.25%), Rockefeller Financial Services Inc. (0.04%), Bartlett & Co. LLC (0.02%), Douglas Lane & Associates LLC (0.01%), BB&T Corp (0.01%) and Park National Corp OH (0.01%). Company insiders that own Novartis AG stock include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Institutional Ownership Trends for Novartis AG.

Who sold Novartis AG stock? Who is selling Novartis AG stock?

Novartis AG's stock was sold by a variety of institutional investors in the last quarter, including Private Asset Management Inc., Douglas Lane & Associates LLC, BB&T Corp, Albert D Mason Inc., Rockefeller Financial Services Inc., Prentiss Smith & Co. Inc., Osborne Partners Capital Management LLC and Canal Capital Management LLC. View Insider Buying and Selling for Novartis AG.

Who bought Novartis AG stock? Who is buying Novartis AG stock?

Novartis AG's stock was bought by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Ingalls & Snyder LLC, Carnick & Kubik Group LLC, Augustine Asset Management Inc., Bartlett & Co. LLC, Park National Corp OH, Beacon Financial Group and Juncture Wealth Strategies LLC. Company insiders that have bought Novartis AG stock in the last two years include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Insider Buying and Selling for Novartis AG.

How do I buy Novartis AG stock?

Shares of Novartis AG can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novartis AG's stock price today?

One share of Novartis AG stock can currently be purchased for approximately $85.74.


MarketBeat Community Rating for Novartis AG (NYSE NVS)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  273 (Vote Outperform)
Underperform Votes:  320 (Vote Underperform)
Total Votes:  593
MarketBeat's community ratings are surveys of what our community members think about Novartis AG and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Novartis AG (NYSE:NVS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 7 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.15)
Consensus Price Target: $82.92 (3.28% downside)
Consensus Price Target History for Novartis AG (NYSE:NVS)
Price Target History for Novartis AG (NYSE:NVS)
Analysts' Ratings History for Novartis AG (NYSE:NVS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/10/2017J P Morgan Chase & CoReiterated RatingNeutralN/AView Rating Details
8/9/2017Cowen and CompanySet Price TargetHold$90.00MediumView Rating Details
7/26/2017Morgan StanleyUpgradeUnderweight -> OverweightLowView Rating Details
7/5/2017Credit Suisse GroupDowngradeNeutral -> Underperform$82.25MediumView Rating Details
6/22/2017Leerink SwannReiterated RatingMarket Perform$83.00LowView Rating Details
6/22/2017Barclays PLCUpgradeUnderweight -> Equal WeightLowView Rating Details
3/22/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutralLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageBuy -> BuyLowView Rating Details
3/7/2017Societe GeneraleUpgradeHold -> Buy$73.82 -> $74.37N/AView Rating Details
3/7/2017BNP ParibasDowngradeNeutral -> UnderperformN/AView Rating Details
1/31/2017ArgusUpgradeHold -> BuyN/AView Rating Details
1/17/2017Berenberg BankDowngradeBuy -> HoldN/AView Rating Details
1/9/2017Deutsche Bank AGReiterated RatingNeutralN/AView Rating Details
10/16/2016Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
10/10/2016Chardan CapitalLower Price TargetBuy$95.00 -> $92.00N/AView Rating Details
7/12/2016Bank of America CorporationReiterated RatingHoldN/AView Rating Details
5/24/2016Citigroup Inc.Reiterated RatingNeutralN/AView Rating Details
11/23/2015VontobelDowngradeHoldN/AView Rating Details
10/28/2015Sanford C. BernsteinLower Price TargetOutperform$102.00N/AView Rating Details
10/28/2015Main First Bank AGDowngradeUnderperformN/AView Rating Details
(Data available from 10/23/2015 forward)

Earnings

Earnings History for Novartis AG (NYSE:NVS)
Earnings by Quarter for Novartis AG (NYSE:NVS)
Earnings History by Quarter for Novartis AG (NYSE NVS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/24/2017$1.25N/AView Earnings Details
7/18/2017Q2 17$1.16$1.22$12.20 billion$12.24 billionViewN/AView Earnings Details
4/25/20173/31/2017$1.10$1.13$11.59 billion$11.54 billionViewN/AView Earnings Details
1/25/2017Q416$1.12$1.12$12.44 billion$12.32 billionViewN/AView Earnings Details
10/25/2016Q316$1.19$1.23$12.24 billion$12.13 billionViewListenView Earnings Details
7/19/2016Q216$1.18$1.23$12.33 billion$12.47 billionViewListenView Earnings Details
4/21/2016Q116$1.18$1.17$11.90 billion$11.60 billionViewListenView Earnings Details
1/27/2016Q415$1.18$1.14$12.64 billion$12.52 billionViewListenView Earnings Details
10/27/2015Q315$1.31$1.27$12.66 billion$12.30 billionViewListenView Earnings Details
7/21/2015Q215$1.20$1.27$12.45 billion$12.70 billionViewListenView Earnings Details
4/23/2015Q115$1.12$1.33$12.90 million$11.94 billionViewN/AView Earnings Details
1/27/2015Q314$1.13$1.21$14.68 billion$14.63 billionViewN/AView Earnings Details
7/17/2014Q214$1.36$1.36$14.83 billion$14.64 billionViewN/AView Earnings Details
4/24/2014Q1 2014$1.33$1.31$14.25 billion$14.02 billionViewN/AView Earnings Details
1/29/2014Q413$1.27$1.20$15.16 billion$15.08 billionViewN/AView Earnings Details
10/22/2013Q313$1.31$1.26$14.28 billion$14.34 billionViewN/AView Earnings Details
7/17/2013Q213$1.29$1.30$14.39 billion$14.50 billionViewN/AView Earnings Details
4/24/2013Q113$1.28$1.32$14.02 million$14.02 billionViewN/AView Earnings Details
1/23/2013Q412$1.19$1.27$14.42 billion$14.80 billionViewN/AView Earnings Details
10/25/2012$1.34$1.34ViewN/AView Earnings Details
7/19/2012$1.33$1.38ViewN/AView Earnings Details
4/24/2012$1.30$1.27ViewN/AView Earnings Details
1/25/2012$1.26$1.23ViewN/AView Earnings Details
10/25/2011$1.45$1.45ViewN/AView Earnings Details
7/19/2011$1.46$1.48ViewN/AView Earnings Details
4/19/2011$1.30$1.41ViewN/AView Earnings Details
1/27/2011$1.25$1.14ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Novartis AG (NYSE:NVS)
2017 EPS Consensus Estimate: $4.75
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$1.08$1.15$1.12
Q2 20172$1.15$1.22$1.19
Q3 20172$1.24$1.25$1.25
Q4 20171$1.20$1.20$1.20
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Novartis AG (NYSE:NVS)
Most Recent Dividend:3/3/2017
Annual Dividend:$2.30
Dividend Yield:2.68%
Dividend Growth:3.90% (3 Year Average)
Payout Ratio:83.94% (Trailing 12 Months of Earnings)
48.42% (Based on This Year's Estimates)
44.06% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Novartis AG (NYSE:NVS)

Dividend History by Quarter for Novartis AG (NYSE NVS)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/27/2017Annual$2.333/1/20173/3/20173/3/2017
2/1/2016Annual$2.342/24/20162/26/20162/26/2016
2/4/2014annual$2.723.48%2/27/20143/3/20143/11/2014
2/11/2013annual$2.533.71%2/26/20132/28/20134/5/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Novartis AG (NYSE:NVS)
Insider Ownership Percentage: 0.01%
Institutional Ownership Percentage: 10.93%
Insider Trades by Quarter for Novartis AG (NYSE:NVS)
Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)
Insider Trades by Quarter for Novartis AG (NYSE:NVS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/5/2017Bioventures Ltd NovartisMajor ShareholderBuy266,667$15.00$4,000,005.00View SEC Filing  
5/11/2016Institutes For Biomed NovartisMajor ShareholderBuy277,777$18.00$4,999,986.00View SEC Filing  
2/17/2016Bioventures Ltd NovartisMajor ShareholderBuy375,000$8.00$3,000,000.00View SEC Filing  
9/22/2014Bioventures Ltd NovartisMajor ShareholderBuy325,000$15.00$4,875,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Novartis AG (NYSE:NVS)
Latest Headlines for Novartis AG (NYSE:NVS)
Source:
Loading headlines, please wait.

Social

Chart

Novartis AG (NVS) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.